US biotech firm Regeneron said Tuesday that its synthetic antibody treatment for Covid-19 may be less effective against the new variant, and it plans to conduct tests to determine by how much.
"Prior in vitro analyses and structural modeling regarding the individual mutations present in the Omicron variant indicate that there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody-conveyed immunity, including the current REGEN-COV antibodies," the company said in a statement.
"Further analyses are ongoing to confirm and quantify this potential impact using the actual Omicron variant sequence."
REGEN-COV is currently authorized in the United States as a post-exposure prophylaxis in high-risk individuals, and is pending full approval.
It is based on two lab-produced monoclonal antibodies -- Y-shaped proteins that bind to the spikes that dot the surface of the coronavirus, stopping the pathogen from invading human cells.
The antibodies, called casirivimab and imdevimab, are injected intravenously.
But Omicron has a high number of mutations on its spike proteins, which worries health experts.
The World Health Organization in late September recommended Regeneron for Covid-19 treatment, but only in patients with specific health profiles, such as the elderly or those with weakened immune systems.
XBB.1.16 Variant Most Dominant Strain Of Covid In India: Health Body 234 Cases Of Mutated Omicron Sub-Variant (XBB1.16.1) Found In India XBB.1.16, New Covid-19 Variant: What We Know So Far Trainee IAS Officer Puja Khedkar Recalled To Academy, Training Put On Hold Under-Fire Trainee IAS Officer Accuses Pune Collector Of Harassment "No Defamatory Remarks Against Governor": High Court To Mamata Banerjee Royal Enfield Guerrilla 450 Launched In India; Prices Start At Rs. 2.39 Lakh Admission Deadline Extended For EWS And Special Needs Children UGC Launches Project To Develop 22,000 Books In Indian Languages Track Latest News Live on NDTV.com and get news updates from India and around the world.